Clinical and Preclinical Outcomes of Combining Targeted Therapy With Radiotherapy

In the era of precision medicine, radiation medicine is currently focused on the precise delivery of highly conformal radiation treatments. However, the tremendous developments in targeted therapy are yet to fulfill their full promise and arguably have the potential to dramatically enhance the radiation therapeutic ratio. The increased ability to molecularly profile tumors both at diagnosis and at relapse and the co-incident progress in the field of radiogenomics could potentially pave the way for a more personalized approach to radiation treatment in contrast to the current ‘‘one size fits all’’ paradigm. Few clinical trials to date have shown an improved clinical outcome when combining targeted agents with radiation therapy, however, most have failed to show benefit, which is arguably due to limited preclinical data. Several key molecular pathways could theoretically enhance therapeutic effect of radiation when rationally targeted either by directly enhancing tumor cell kill or indirectly through the abscopal effect of radiation when combined with novel immunotherapies. The timing of combining molecular targeted therapy with radiation is also important to determine and could greatly affect the outcome depending on which pathway is being inhibited.

Abstract licence: CC BY

1. 38.

   Delayed repair of radiation induced clustered DNA damage: Friend or foe? · 2011

2. 55.

   Irradiation Promotes an M2 Macrophage Phenotype in Tumor Hypoxia · 2012

3. 72.

   The Effect of Radiation on the Immune Response to Cancers · 2014

4. 113.

   Determination of cell survival after irradiation via clonogenic assay versus multiple MTT Assay - A comparative study · 2012

5. 144.

   A genetic basis for the variation in the vulnerability of cancer to DNA damage · 2016

6. 149.

   The anti-malarial atovaquone increases radiosensitivity by alleviating tumour hypoxia · 2016

7. 176.

   Exploiting the Ref-1-APE1 node in cancer signaling and other diseases: from bench to clinic · 2017

8. 183.

   Poly-(ADP-ribose)-polymerase inhibitors as radiosensitizers: a systematic review of pre-clinical and clinical human studies · 2017

9. 191.

   Mitochondrial metabolism and cancer · 2017

10. 207.

    Role of metabolism in cancer cell radioresistance and radiosensitization methods · 2018

11. 209.

    Efficient generation of mouse models of human diseases via ABE- and BE-mediated base editing · 2018

12. 220.

    Nanoscale metal-organic frameworks for mitochondria-targeted radiotherapy-radiodynamic therapy · 2018

13. 224.

    Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trial · 2019

14. 227.

    Targeting DNA Double-Strand Break Repair Pathways to Improve Radiotherapy Response · 2019

15. 234.

    Cancer-associated fibroblasts in radiotherapy: challenges and new opportunities · 2019

16. 256.

    Clustered DNA Double-Strand Breaks: Biological Effects and Relevance to Cancer Radiotherapy · 2020

17. 269.

    DNA damage response signaling pathways and targets for radiotherapy sensitization in cancer · 2020

18. 273.

    VISTA: an immune regulatory protein checking tumor and immune cells in cancer immunotherapy · 2020

19. 281.

    Advances in synthetic lethality for cancer therapy: cellular mechanism and clinical translation · 2020

292 more references, whose wording the paper’s licence keeps private.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.